SCHEMBL19682744

SCHEMBL19682744

C[C@H](c1cccc2ccccc12)[C@H](N)C(=O)O

nearest known ligand 0.48

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.48
SLC1A2 P43004 2/20 0.48
SLC1A1 P43005 2/20 0.48
ALOX5 P09917 1/20 0.48
ALDH1A1 P00352 2/20 0.48
METAP2 P50579 3/20 0.45
METAP1 P53582 3/20 0.45
CYP2C9 P11712 2/20 0.43
CYP2C19 P33261 2/20 0.43
HPGD P15428 1/20 0.43
HTT P42858 1/20 0.43
ECE1 P42892 1/20 0.43
CYP1A2 P05177 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
EPHX2 P34913 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5326799 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL29628527 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL7366366 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL26966061 1.00 SLC1A3 (0.48) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL6460441 0.90 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL6460442 0.90 SLC1A3 (0.46) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL5028930 0.87 ALOX5 (0.48) ALOX5ALDH1A1METAP2METAP1CYP2C9
SCHEMBL6464059 0.86 ALDH1A1 (0.49) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL6464051 0.86 ALDH1A1 (0.49) SLC1A3SLC1A2SLC1A1ALOX5ALDH1A1
SCHEMBL19682577 0.82 SLC1A1 (0.42) SLC1A3SLC1A2SLC1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3466934-B1 SULFONAMIDE COMPOUNDS OR SALT THEREOF AS RIBONUCLEOTIDE REDUCTASE INHIBITORS FOR TREATING CANCER TAIHO PHARMACEUTICAL CO LTD (JP) 2024-03-27 EP disclosed
US-11634395-B2 Sulfonamide compound or salt thereof Taiho Pharmaceutial Co., Ltd. (JP) 2023-04-25 US disclosed
CN-109563057-B Sulfonamide compound or salt thereof 大鹏药品工业株式会社 2022-06-24 CN disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-10889555-B2 Sulfonamide compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-01-12 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200405697-A1 Antitumor Agent TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-31 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
US-20200399235-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-12-24 US disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
EP-3718545-A1 ANTITUMOR AGENT Taiho Pharmaceutical Co., Ltd. (JP) 2020-10-07 EP disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
US-20200157066-A1 Sulfonamide Compound or Salt Thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-05-21 US disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
EP-3466934-A1 SULFONAMIDE COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2019-04-10 EP disclosed
WO-2017209155-A1 SULFONAMIDE COMPOUND OR SALT THEREOF 大鵬薬品工業株式会社 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200399235-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 SLC1A3 3645/4885SLC1A2 4159/4885SLC1A1 3403/4885
US-20200157066-A1 Sulfonamide Compound or Salt Thereof RNASEH1, SNRPA1, RRM2 SLC1A3 3645/4885SLC1A2 4159/4885SLC1A1 3403/4885
US-10889555-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 SLC1A3 3645/4885SLC1A2 4159/4885SLC1A1 3403/4885
US-11634395-B2 Sulfonamide compound or salt thereof RNASEH1, SNRPA1, RRM2 SLC1A3 3645/4885SLC1A2 4159/4885SLC1A1 3403/4885
US-20200405697-A1 Antitumor Agent HNRNPR, RRM2, RRM2B SLC1A3 3275/4885SLC1A2 4106/4885SLC1A1 3066/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.